Be part of the knowledge.™

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.

3667

LikeLikedUnlike

841-855 of 1026

Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits
CME/CE
Making the Case for Dual Ang-2/VEGF-A Inhibition: Anatomical Benefits
- Jennifer I. Lim, MD, FARVO
- Carl Regillo, MD
0.25 credits
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
CME/CE
Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab
- Sara M. Tolaney, MD, MPH
0.25 credits
Getting to the Root of CKD-Associated Pruritus: Questions From the Field
CME/CE
Getting to the Root of CKD-Associated Pruritus: Questions From the Field
- Joel Topf, MD
- James Burton, DM, FRCP
0.25 credits
Overcoming Clinical Inertia in Hyperkalemia Management
CME/CE
Overcoming Clinical Inertia in Hyperkalemia Management
- Peter Rossing, MD, DMSc
- Michael Böhm, MD, FESC
- Luca De Nicola, MD, PhD
0.25 credits
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
CME/CE
Duchenne Muscular Dystrophy: Differentiating Advances in Treatment
- Omer Abdul Hamid, MD
- Nancy Kuntz, MD
- Migvis Monduy, MD
0.25 credits
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
CME/CE
Making the Case for Dual Ang-2 VEGF-A Inhibition: Durability and Drying
- Carl Regillo, MD
- Jennifer I. Lim, MD, FARVO
0.25 credits
advertisement
Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program
CME/CE
Beyond BeAT-HF: Integrating Barostim into a Comprehensive HF Program
- Dmitry M. Yaranov, MD
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
CME/CE
Applying SDM to Personalize Treatment Discussions on Recurrence Risk Reduction in Patients with Early-Stage Melanoma
- Meghan Mooradian, MD
0.25 credits
Emerging Therapeutics in ADH1: Progress in Precision Medicine
MinuteCE®
Emerging Therapeutics in ADH1: Progress in Precision Medicine
- Michael A. Levine, MD, FAAP, MACE, FACP
- B. Michelle Schweiger, DO, MPH
1.00 program credits
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
MinuteCE®
Increasing ADH1 Awareness: A Hidden Cause of Hypoparathyroidism
- Michael A. Levine, MD, FAAP, MACE, FACP
- B. Michelle Schweiger, DO, MPH
1.00 program credits
MinuteCE®
The Future of ADH1 - Looking at Emergent Treatments
- Michael A. Levine, MD, FAAP, MACE, FACP
- B. Michelle Schweiger, DO, MPH
1.00 credits 4 episodes
Therapeutic Options for ADH1 and Hypoparathyroidism
MinuteCE®
Therapeutic Options for ADH1 and Hypoparathyroidism
- Michael A. Levine, MD, FAAP, MACE, FACP
- B. Michelle Schweiger, DO, MPH
1.00 program credits
advertisement
CASR and ADH1: Integrating Biology and Genetic Screening
MinuteCE®
CASR and ADH1: Integrating Biology and Genetic Screening
- Michael A. Levine, MD, FAAP, MACE, FACP
- B. Michelle Schweiger, DO, MPH
1.00 program credits
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
- Jyoti Patel, MD
- Pasi Antero Jänne, MD, PhD
0.50 credits
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
CME/CE
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
- Helena Yu, MD
0.25 credits

Program Chapters

Segment Chapters

Playlist:

Recommended